⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

ND0612 Infusion Dramatically Reduces OFF-time and Improves Quality of Life in Parkinson’s Disease: A Meta-analysis of Randomized Trials (P8-17.009)

Shenney Lin Jamir Pitton Rissardo Omar Elmandouh Ana Leticia Fornari Caprara Ian M. Walker

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to assess how effective ND0612 is compared to placebo and existing oral therapies for Parkinson's disease.
Meta-analysis of randomized trials comparing ND0612 to placebo or current oral therapy.
Evaluated changes in OFF-time and quality of life.
Focused specifically on patients diagnosed with Parkinson’s disease.
ND0612 infusion significantly reduced OFF-time compared to placebo.
Marked improvement in quality of life metrics among patients receiving ND0612.
Findings support the efficacy of ND0612 in managing Parkinson’s disease symptoms.

Implication

Randomized trial evaluates ND0612's effects on OFF-time and quality of life in Parkinson’s disease, indicating significant benefits.

Abstract

To evaluate the efficacy of ND0612 compared with placebo or current oral therapy in patients with Parkinson’s disease (PD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0563b3 https://doi.org/10.1212/wnl.0000000000215020

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reductions in OFF Time with ND0612 for People with Parkinson’s Disease Experiencing Motor Fluctuations: Responder-analysis from an Open-label Study (P9-3.019)2024 · 1 citations
2Efficacy of ND0612, a 24-hour Subcutaneous Levodopa/Carbidopa Infusion for People with Parkinson’s Disease Experiencing Motor Fluctuations: Subgroup-analyses from a Randomized, Controlled Phase 3 Study (S30.008)2024
3Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta‐AnalysisHuman Clinical Trial · 2026 · 2 citations
4Continuous subcutaneous levodopa and foslevodopa infusion therapy for motor symptoms of Parkinson disease: A systematic review of observational studiesSystematic Review · 2026 · 1 citations
5Onset of Efficacy with Continuous, Subcutaneous Levodopa/carbidopa Infusion in Patients with Parkinson’s Disease Experiencing Motor Fluctuations (P9-3.012)2024

More related papers

Infusion therapies for advanced Parkinson’s disease: current evidence and practical challenges — a narrative review2026
Optimizing a Patient’s Oral CD-LD Dosing Regimen Is Critical for Improving Efficacy in Parkinson’s Disease (P4-3.019)2024
Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson’s Disease: A Systematic Review2026

More from Neurology

Recanalization After Acute Cervical Artery DissectionTue,
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSDTue,